SYNEOS HEALTH UK LIMITED

Women remain underrepresented in clinical trials, prompting the launch of Lindus Health's women's health-focused CRO. This CRO aims to address historical gaps by considering ethical and social factors, ensuring true informed consent, and developing strategies to overcome social barriers. Despite increased industry attention, diversity in clinical trials continues to suffer, with underrepresented groups like Black patients, elderly, disabled, indigenous, and transgender and nonbinary people lacking adequate representation. Boosting participation among these groups presents a market opportunity for sponsors.

The U.S. clinical trials market is projected to reach USD 57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominate with the highest revenue share, and oncology holds the largest segment due to rising cancer cases. Key players include IQVIA, Fortrea, PAREXEL, and Thermo Fisher Scientific.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology leading by indication. Key players include IQVIA, Fortrea Inc., and PAREXEL International Corporation.

The U.S. clinical trials market is projected to grow to USD 57.79 billion by 2030, driven by chronic diseases and cancer prevalence. Phase III trials dominate due to their scale and cost. Oncology leads in indication, reflecting high cancer case numbers and R&D investment. Key players include IQVIA, PAREXEL, and Pfizer.

The Pharmacovigilance and Drug Safety Software Market is expected to grow from USD 206.68 million in 2023 to USD 371.88 million by 2032, at a CAGR of 6.76%. This growth is driven by increasing drug approvals, stringent regulatory compliance, and the integration of AI and ML technologies for enhanced pharmacovigilance processes.

The article discusses the low enrollment of Black patients in multiple myeloma trials like IMROZ and PERSEUS, despite the disease disproportionately affecting this population. It highlights the FDA's efforts to address this through Diversity Action Plans and emphasizes the need for systemic change to ensure equitable participation in clinical trials.

The Functional Service Providers (FSP) Market was valued at USD 14.68 billion in 2023 and is projected to reach USD 30.70 billion by 2032, growing at a CAGR of 8.56%. The market's expansion is driven by the complexity of clinical trials, increased R&D investments, and the need for specialized services. Pharmaceutical and biotechnology companies are increasingly outsourcing to optimize trial efficiency and reduce costs. FSPs leverage technologies like AI and big data analytics to enhance trial design and execution. The market is segmented by type, stage, and application, with North America leading and Asia Pacific expected to grow the fastest.

Offshoring clinical trials market is rapidly expanding due to cost savings, quicker patient recruitment, and access to diverse populations, particularly in Asia-Pacific, Latin America, and Eastern Europe. Key factors driving growth include regulatory harmonisation, digital health tools, and remote monitoring. The market is projected to reach 12.4 billion USD by 2033, growing at a CAGR of 9.1%.

Decentralized clinical trials, facilitated by tech like remote monitoring and telemedicine, are expanding access to diverse patient populations and accelerating timelines. Companies like Allucent, Curavit, EmVenio, ObvioHealth, PPD, Science 37, and Vivalink are leading in this space, offering solutions that conduct trials outside traditional settings, enhancing patient-centricity and data quality.

CytoDyn finalized a phase 2 study protocol for leronlimab in relapsed/refractory microsatellite stable colorectal cancer, gaining FDA clearance. The trial, in partnership with Syneos Health, is set to start in November 2024, with patient enrollment in early 2025. Leronlimab, combined with TAS-102 and bevacizumab, targets CCR5+ MSS mCRC patients who have undergone multiple treatments.